Kamada (NASDAQ:KMDA) Shares Cross Below 200 Day Moving Average - Here's What Happened

Key Points

• Kamada Ltd. (NASDAQ: KMDA) shares dipped below their 200-day moving average of $7.07, trading as low as $6.92 before closing at $7.05 on Thursday.
• Analysts maintain a positive outlook for Kamada, with two offering a "Buy" rating and one a "Hold," alongside a consensus price target of $13.00.
• The company reported $0.13 EPS for the last quarter, surpassing analyst expectations, but its revenue fell significantly short of estimates at $44.75 million.

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $7.07 and traded as low as $6.92. Kamada shares last traded at $7.05, with a volume of 28,312 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on KMDA shares. Benchmark reiterated a "buy" rating and issued a $15.00 price target on shares of Kamada in a research report on Thursday, May 15th. Wall Street Zen upgraded Kamada from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, May 21st. Finally, Sidoti upgraded Kamada to a "hold" rating in a research report on Thursday, May 8th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $13.00.

Kamada Price Performance

The firm has a fifty day simple moving average of $7.48 and a 200-day simple moving average of $7.07. The firm has a market cap of $410.05 million, a P/E ratio of 20.97, a price-to-earnings-growth ratio of 0.75 and a beta of 0.93.

Kamada (NASDAQ:KMDA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.04. The business had revenue of $44.75 million for the quarter, compared to analyst estimates of $158.59 million. Kamada had a return on equity of 7.41% and a net margin of 11.22%. Kamada has set its FY 2025 guidance at EPS. On average, equities analysts predict that Kamada Ltd. will post 0.23 earnings per share for the current year.

Institutional Trading of Kamada

Several institutional investors and hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC increased its position in shares of Kamada by 3.1% during the second quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company's stock valued at $2,053,000 after acquiring an additional 7,925 shares during the last quarter. ARK Investment Management LLC purchased a new stake in shares of Kamada during the second quarter valued at approximately $1,972,000. Huntleigh Advisors Inc. increased its position in shares of Kamada by 3.9% during the second quarter. Huntleigh Advisors Inc. now owns 135,776 shares of the biotechnology company's stock valued at $1,052,000 after acquiring an additional 5,151 shares during the last quarter. Jane Street Group LLC purchased a new stake in Kamada in the first quarter worth $582,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Kamada in the first quarter worth $497,000. 20.38% of the stock is owned by hedge funds and other institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.